BRPI0720220B8 - derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo - Google Patents
derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmoInfo
- Publication number
- BRPI0720220B8 BRPI0720220B8 BRPI0720220A BRPI0720220A BRPI0720220B8 BR PI0720220 B8 BRPI0720220 B8 BR PI0720220B8 BR PI0720220 A BRPI0720220 A BR PI0720220A BR PI0720220 A BRPI0720220 A BR PI0720220A BR PI0720220 B8 BRPI0720220 B8 BR PI0720220B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- combination
- product
- pharmaceutical composition
- preparation process
- Prior art date
Links
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06125499 | 2006-12-06 | ||
| PCT/EP2007/063313 WO2008068267A1 (en) | 2006-12-06 | 2007-12-04 | Antibacterial quinoline derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0720220A2 BRPI0720220A2 (pt) | 2013-12-24 |
| BRPI0720220B1 BRPI0720220B1 (pt) | 2020-06-09 |
| BRPI0720220B8 true BRPI0720220B8 (pt) | 2021-05-25 |
Family
ID=38126091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0720220A BRPI0720220B8 (pt) | 2006-12-06 | 2007-12-04 | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8415475B2 (enExample) |
| EP (1) | EP2099758B1 (enExample) |
| JP (1) | JP5466011B2 (enExample) |
| KR (1) | KR101490222B1 (enExample) |
| CN (2) | CN104744361B (enExample) |
| AP (1) | AP2479A (enExample) |
| AR (1) | AR064151A1 (enExample) |
| AU (1) | AU2007328887B2 (enExample) |
| BR (1) | BRPI0720220B8 (enExample) |
| CA (1) | CA2669819C (enExample) |
| CL (1) | CL2007003514A1 (enExample) |
| CY (1) | CY1117766T1 (enExample) |
| DK (1) | DK2099758T3 (enExample) |
| EA (1) | EA016733B1 (enExample) |
| ES (1) | ES2573689T3 (enExample) |
| HR (1) | HRP20160585T1 (enExample) |
| HU (1) | HUE028769T2 (enExample) |
| IL (1) | IL199083A (enExample) |
| JO (1) | JO3271B1 (enExample) |
| ME (1) | ME02498B (enExample) |
| MX (1) | MX2009005978A (enExample) |
| MY (1) | MY181645A (enExample) |
| NO (1) | NO341983B1 (enExample) |
| NZ (1) | NZ576823A (enExample) |
| PL (1) | PL2099758T3 (enExample) |
| PT (1) | PT2099758E (enExample) |
| RS (1) | RS54794B1 (enExample) |
| SI (1) | SI2099758T1 (enExample) |
| TW (1) | TWI406659B (enExample) |
| UA (1) | UA100972C2 (enExample) |
| WO (1) | WO2008068267A1 (enExample) |
| ZA (1) | ZA200903950B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2576491T3 (es) | 2012-04-27 | 2016-07-07 | Janssen Pharmaceutica, N.V. | Derivados de quinolina antibacterianos |
| AU2013254670B2 (en) | 2012-04-27 | 2017-03-30 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| MY189505A (en) | 2012-10-16 | 2022-02-16 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of roryt |
| WO2014062655A1 (en) | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt |
| HK1213887A1 (zh) | 2012-10-16 | 2016-07-15 | Janssen Pharmaceutica N.V. | RORγt的苯基连接的喹啉基调节剂 |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| CA2927182A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Quinolinyl modulators of ror.gamma.t |
| CA2926339A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of roryt |
| CN105330595B (zh) * | 2014-07-14 | 2019-12-10 | 上海嘉坦医药科技有限公司 | 吡啶衍生物及其作为抗分支杆菌的应用 |
| JP6362235B2 (ja) * | 2014-07-14 | 2018-07-25 | ツーセン ファーマシューティカル カンパニー リミテッド | ピリジン誘導体およびその抗マイコバクテリウムにおける使用 |
| KR102631986B1 (ko) * | 2015-01-27 | 2024-01-30 | 얀센 파마슈티카 엔브이 | 분산성 조성물 |
| CN108473428B (zh) * | 2016-01-13 | 2021-07-23 | 上海嘉坦医药科技有限公司 | 一种吡啶衍生物类化合物的制备方法及其中间体和晶型 |
| CN105601566A (zh) * | 2016-02-02 | 2016-05-25 | 张敏 | 一种护理烧伤后感染的药物组合物 |
| EA201891644A1 (ru) * | 2016-03-07 | 2019-04-30 | Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. | Антибактериальные соединения и их применение |
| US11857352B2 (en) | 2016-09-06 | 2024-01-02 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| JP2021511364A (ja) * | 2018-01-29 | 2021-05-06 | カディラ ヘルスケア リミティド | 抗菌剤として有用な複素環式化合物 |
| WO2022084947A1 (en) * | 2020-10-22 | 2022-04-28 | Lunella Biotech, Inc. | Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965572A (en) | 1996-10-28 | 1999-10-12 | The United States Of America As Respresented By The Secretary Of The Army | Methods for treating antibiotic-resistant infections |
| SI1527050T1 (sl) * | 2002-07-25 | 2010-08-31 | Janssen Pharmaceutica Nv | Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji |
| US7902225B2 (en) * | 2004-01-23 | 2011-03-08 | Janssen Pharmaceutica Nv | Mycobacterial inhibitors |
| BRPI0507076B8 (pt) | 2004-01-23 | 2021-05-25 | Janssen Pharmaceutica Nv | quinolinas substituídas, seu processo de preparação, composição farmacêutica que as compreende e seu uso como inibidores micobacterianos |
| UA83875C2 (ru) * | 2004-01-29 | 2008-08-26 | Янссен Фармацевтика Н.В. | Производные хинолина для применения в качестве микобактериальных ингибиторов |
| MXPA06013888A (es) * | 2004-05-28 | 2007-01-26 | Janssen Pharmaceutica Nv | Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos. |
| RS56357B1 (sr) | 2004-09-28 | 2017-12-29 | Janssen Pharmaceutica Nv | Vezujući domen bakterijske atp sintaze |
| EE05394B1 (et) | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| CA2528849C (en) * | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Quinoline derivatives as antibacterial agents |
| JO2952B1 (en) * | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO2855B1 (en) * | 2005-08-03 | 2015-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO2837B1 (en) * | 2005-08-03 | 2014-09-15 | جانسن فارمسيتكا ان في | Quinoline derivatives acting as antibacterial agents |
-
2007
- 2007-11-29 JO JOP/2007/0504A patent/JO3271B1/ar active
- 2007-12-04 HR HRP20160585TT patent/HRP20160585T1/hr unknown
- 2007-12-04 SI SI200731779A patent/SI2099758T1/sl unknown
- 2007-12-04 AU AU2007328887A patent/AU2007328887B2/en not_active Ceased
- 2007-12-04 CN CN201510088659.1A patent/CN104744361B/zh not_active Expired - Fee Related
- 2007-12-04 RS RS20160374A patent/RS54794B1/sr unknown
- 2007-12-04 PL PL07847811T patent/PL2099758T3/pl unknown
- 2007-12-04 PT PT07847811T patent/PT2099758E/pt unknown
- 2007-12-04 UA UAA200904716A patent/UA100972C2/ru unknown
- 2007-12-04 MY MYPI20092283A patent/MY181645A/en unknown
- 2007-12-04 WO PCT/EP2007/063313 patent/WO2008068267A1/en not_active Ceased
- 2007-12-04 US US12/516,065 patent/US8415475B2/en not_active Expired - Fee Related
- 2007-12-04 CN CNA2007800449358A patent/CN101553470A/zh active Pending
- 2007-12-04 KR KR1020097012967A patent/KR101490222B1/ko not_active Expired - Fee Related
- 2007-12-04 MX MX2009005978A patent/MX2009005978A/es active IP Right Grant
- 2007-12-04 EP EP07847811.2A patent/EP2099758B1/en active Active
- 2007-12-04 ES ES07847811.2T patent/ES2573689T3/es active Active
- 2007-12-04 HU HUE07847811A patent/HUE028769T2/en unknown
- 2007-12-04 NZ NZ576823A patent/NZ576823A/en not_active IP Right Cessation
- 2007-12-04 AP AP2009004874A patent/AP2479A/xx active
- 2007-12-04 JP JP2009539738A patent/JP5466011B2/ja not_active Expired - Fee Related
- 2007-12-04 CA CA2669819A patent/CA2669819C/en active Active
- 2007-12-04 ME MEP-2016-109A patent/ME02498B/me unknown
- 2007-12-04 DK DK07847811.2T patent/DK2099758T3/en active
- 2007-12-04 BR BRPI0720220A patent/BRPI0720220B8/pt not_active IP Right Cessation
- 2007-12-04 EA EA200970535A patent/EA016733B1/ru unknown
- 2007-12-05 CL CL200703514A patent/CL2007003514A1/es unknown
- 2007-12-05 TW TW096146217A patent/TWI406659B/zh not_active IP Right Cessation
- 2007-12-05 AR ARP070105444A patent/AR064151A1/es unknown
-
2009
- 2009-06-02 IL IL199083A patent/IL199083A/en active IP Right Grant
- 2009-06-05 ZA ZA200903950A patent/ZA200903950B/xx unknown
- 2009-07-06 NO NO20092542A patent/NO341983B1/no unknown
-
2016
- 2016-06-08 CY CY20161100496T patent/CY1117766T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0719920B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário | |
| CY1117766T1 (el) | Αντιβακτηριδιακα παραγωγα κινολινης | |
| BR122019010200B8 (pt) | compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas | |
| BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
| BRPI0821115A8 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| BRPI0510414A (pt) | uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| EA201170249A1 (ru) | 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ | |
| BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
| BR112015016315A2 (pt) | fluoro-[1,3]oxazinas como inibidores de bace1 | |
| BR112012017269A2 (pt) | compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos | |
| ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
| BR112015019412A2 (pt) | inibidores de bace1 | |
| BR112014003063A2 (pt) | "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso". | |
| BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
| BRPI0719939B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo | |
| CY1112230T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
| BRPI0720251B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo | |
| BRPI0614122A8 (pt) | composto derivado de quinolina, composição farmacêutica e uso do referido composto | |
| BRPI0613999B8 (pt) | uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto | |
| CY1112027T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
| BR112023017040A2 (pt) | Derivados de indolina como inibidores de ddr1 e ddr2 | |
| BRPI0612534B8 (pt) | uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto | |
| BR112014026776A2 (pt) | derivados de pirimidina para o tratamento de doenças bacterianas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/06/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2804 DE 01-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |